Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

92.34 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
35 36 Next >
Biotech Stocks To Watch And Pharma Industry News
Track the latest trends and leading stocks in the biotech and pharmaceutical industries. 
Via Investor's Business Daily
7 Best Biotech Stocks to Buy in July 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. 
Via InvestorPlace
Biotechs Say ESG Is Core To Their Mission; Do Investors Believe Them?
The biotech industry is trying to catch the ESG investing bug. But that doesn't mean investors are giving it credit, executives say. 
Via Investor's Business Daily
Q2 Earnings: Energy and What Else?
S&P 500 earnings are expected to be up 2.5% year-over-year on 10.8% higher revenues. But much of that is attributed to energy, which is expected to have another record quarter. 
Via Talk Markets
HC Wainwright Finds 'Synergies In Treatment' For This Bipolar-Focused Stock
Via Benzinga
Recent Stock Purchase June 2022
I make a stock purchase every single month no matter what is going on in the world and despite the doom and gloom headlines. 
Via Talk Markets
AstraZeneca's COVID-19 Treatment Allowed In China's Southern City: Reuters
Via Benzinga
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
$1000 Invested In Gilead Sciences 15 Years Ago Would Be Worth This Much Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 15 years by 1.74% on an annualized basis producing an average annual return of 8.04%. Currently, Gilead Sciences has a market... 
Via Benzinga
The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Gilead Again Seeks HIV Drug Approval From FDA After Addressing Vial Compatibility Issues
Gilead Sciences (NASDAQ: GILD) resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the... 
Via Benzinga
From Axcella To Tonix, Here Are The Penny Stocks Of Companies Working On Long Covid
More than four in 10 people in a recent survey knew of someone with long Covid. 
Via Investor's Business Daily
7 Biotech Stocks With Key Catalysts Coming in July
Biotech stocks have had a rocky few months, but many are on the mend. These picks should provide investors both flexibility and growth. 
Via InvestorPlace
Traders See Bumpy Road Ahead For Gilead Sciences
Gilead Sciences, Inc. (NASDAQ: GILD) climbed on Wednesday, even as the S&P 500 ended the day with losses. 
Via Benzinga
Monkeypox Could Reportedly Trigger An Uptick In Sepsis Cases But This Israeli Biotech Company Says It May Have Found A Treatment
As the mysterious monkeypox outbreak has many scientists on heightened alert, the rare virus could pose an additional threat to a global population still reeling from the COVID-19 pandemic. 
Via Benzinga
Why Gilead Is Cheapest Large-Cap Biotech Despite Some Not So Favorable Acquisitions
Even after spending over $40 billion in the past five years on acquisitions, none of the deals for Gilead Sciences Inc (NASDAQ: GILD) has delivered the blockbuster in cancer as it looked to venture... 
Via Benzinga
Analysts Remain Bullish Despite Caribou's Allogeneic CAR-T Hit By Durability
Via Benzinga
Here's How Much $100 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 15 years by 1.22% on an annualized basis producing an average annual return of 7.45%. Currently, Gilead Sciences has a market... 
Via Benzinga
What's Next For NRx Pharma As FDA Denies Breakthrough Therapy Tag For COVID-19 Therapy
Via Benzinga
There Are Some Serious Deals In The Market Right Now
Interested in buying high-quality dividend growth stocks on sale? Want to know my top five stocks for June 2022? Then you have to check out this video. 
Via Talk Markets
7 Great ETFs to Buy Now for Momentum in Q2
These seven ETFs to buy are among the best funds. YPS, BITQ, FMET, QQMG, DVY, XSD, and VHT can make excellent investments. 
Via InvestorPlace
Sunshine Biopharma States It Is Developing COVID Antiviral That Could Play Important Role In Treating Endemic COVID
Image provided by Pexels 
Via Benzinga
7 Oversold Stocks to Buy Right Now
Identifying oversold stocks gives investors the opportunity to buy shares that they perhaps already liked, only at a discounted price. 
Via InvestorPlace
June 2022 Stock Considerations
With the start of a new trading month, it is time, once again, to highlight some potential stock buys for June. 
Via Talk Markets
7 Safe Dividend Stocks With High Yields to Buy Now
Investors are seeking dividend stocks. Here are seven safe dividend stocks that offer a high yield to maximize their total return. 
Via InvestorPlace
Why NRX Pharmaceuticals Shares Are Trading Lower During Premarket On Thursday?
Via Benzinga
Murder For Hire? What You Need To Know About Enochian Biosciences Co-Founder's Arrest
The co-founder of Enochian Biosciences Inc (NASDAQ: ENOB) was arrested Wednesday following a two-year investigation into a man who was kidnapped and found dead in January 2018. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
Via Benzinga
Recent Stock Purchase May 2022
I have been busy buying up some stock this month and was happy to put some fresh capital to work to try and recoup some of my lost dividend income courtesy of the numerous cuts bestowed upon my... 
Via Talk Markets
Gilead Stock Earns Rating Upgrade After Quick Turnaround
A Relative Strength Rating upgrade for Gilead stock shows improving technical performance. Will it continue? 
Via Investor's Business Daily
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.